For GSK, Lots Of Drugs In R&D, But Many Are Long-Term
This article was originally published in Scrip
GlaxoSmithKline PLC held an expansive R&D update Nov. 3, laying out a strategy to file up to 20 drugs with regulators before 2020, seven of which could launch in that timeline. But few investors are likely to walk away from the four-hour meeting with a changed sentiment on the firm in the near-term, where it is facing strong headwinds from slowing sales of its top-seller Advair Diskus.
You may also be interested in...
The race to market for HIF-PH inhibitors to treat anemia associated with chronic kidney disease is highly competitive and will be complicated by the expected launch of biosimilar erythropoiesis-stimulating agents.
The British pharma outlined its strategy for winning as one of the world’s leading vaccines makers May 6, two months after completing the acquisition of Novartis’ vaccines business.
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.